Congress demands real-time alerts on infant formula contamination
H.R. 7867 — Infant Formula Safety Modernization Act of 2026 · Filed by Rosa DeLauro (D-CT) · 43 cosponsors · Introduced Mar 9, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires infant formula manufacturers to test their facilities and finished products for dangerous pathogens (including botulism) and report positive results to the FDA within one business day. The FDA must then notify Congress within one business day of any positive test or serious inspection failure. The bill mandates the FDA issue detailed testing and inspection standards within 90 days.
Why we flagged it
The bill's operative mechanism is a direct regulatory mandate requiring manufacturers to test for pathogens and report results to the FDA and Congress. It is a safety-driven accountability measure, not a market intervention or subsidy.
What the text implies
- Congressional notification requirement creates a real-time legislative oversight channel for infant formula safety crises, potentially enabling faster legislative response than traditional FDA-only reporting.
- One-business-day reporting deadline for positive tests may accelerate market withdrawal of contaminated batches, reducing consumer exposure window but potentially creating supply-chain volatility if multiple facilities report simultaneously.
The full analysis lists 4 implications of this text.
Who it affects
Ordinary citizens—especially parents of infants—gain direct protection through mandatory pathogen testing, faster detection of contamination, and congressional oversight of safety failures. The bill imposes no new costs on consumers and strengthens accountability for a product critical to infant health and survival.